Mining fungal genomes, LifeMine plots future with $175M series C, GSK partnership

As fungus-derived theraputics developer LifeMine moves high-priority internal programs toward the clinic, the start-up’s high-profile leadership team has chosen GSK as its first major partner for a three-target deal.

Co-founded by Harvard University professor Gregory Verdine and serial entrepreneur Rick Klausner along with WuXi Healthcare Ventures entrepreneur-in-residence WeiQing Zhou, LifeMine Therapeutics Inc. interrogates its respository of fungal isolates to identify compounds predicted to show activity against targets of interest...